Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525447 · ClinicalTrials.gov registry record · Phase 1
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00525447 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 36 participants.
The verdict
NCT00525447, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
Interventions
- DRUG dexamethasone
- DRUG lenalidomide
- DRUG SGN-40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525447
The ClinicalTrials.gov registry entry for NCT00525447 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT00525447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00525447 about?
NCT00525447 is a clinical study titled "Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma". This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
What is the current status of trial NCT00525447?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-08. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00525447?
The interventions under investigation include: dexamethasone (DRUG), lenalidomide (DRUG), SGN-40 (DRUG).
Who is sponsoring clinical trial NCT00525447?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.